Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy

Robert T. Eagan, Thomas R. Fleming, Robert E. Lee, James N. Ingle, Stephen Frytak, Edward T. Creagan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Twenty-two patients with limited unresectable squamous cell lung cancer were treated with 6 courses of combination chemotherapy consisting of cyclophosphamide, adriamycin, cisplatin, and bleomycin (CAP-Bleo) and short-course thoracic irradiation started after the first 4 weeks of chemotherapy. Of 20 patients with visible tumor who were treated with 4 weeks of chemotherapy alone, 10 (50 %) had a tumor regression in that 4 week period and 10 did not. Those patients with tumor regression had significantly better progression free and overall survivals than did patients with no chemotherapy regressions (medians of 258 days vs. 136 days and 356 days vs. 150 days respectively). The original bleomycin dose had to be reduced by 50 % primarily because of excessive radiation esophagitis that has not been reported with use of either the CAP regimen or bleomycin along in conjunction with thoracic irradiation. An initial chemotherapy regression seems to be a good prognosticator for progression-free and overall survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy.

Original languageEnglish (US)
Pages (from-to)879-883
Number of pages5
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume6
Issue number7
DOIs
StatePublished - 1980

Fingerprint

Squamous Cell Neoplasms
chemotherapy
lungs
radiation therapy
Lung Neoplasms
Radiotherapy
cancer
Drug Therapy
Survival
Bleomycin
tumors
Disease-Free Survival
progressions
Thorax
regression analysis
Neoplasms
Esophagitis
Combination Drug Therapy
irradiation
Doxorubicin

Keywords

  • Chemotherapy
  • Radiation therapy
  • Squamous cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy. / Eagan, Robert T.; Fleming, Thomas R.; Lee, Robert E.; Ingle, James N.; Frytak, Stephen; Creagan, Edward T.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 6, No. 7, 1980, p. 879-883.

Research output: Contribution to journalArticle

Eagan, Robert T. ; Fleming, Thomas R. ; Lee, Robert E. ; Ingle, James N. ; Frytak, Stephen ; Creagan, Edward T. / Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy. In: International Journal of Radiation Oncology, Biology, Physics. 1980 ; Vol. 6, No. 7. pp. 879-883.
@article{687980eb0a934cd6a24abb9fd48c421c,
title = "Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy",
abstract = "Twenty-two patients with limited unresectable squamous cell lung cancer were treated with 6 courses of combination chemotherapy consisting of cyclophosphamide, adriamycin, cisplatin, and bleomycin (CAP-Bleo) and short-course thoracic irradiation started after the first 4 weeks of chemotherapy. Of 20 patients with visible tumor who were treated with 4 weeks of chemotherapy alone, 10 (50 {\%}) had a tumor regression in that 4 week period and 10 did not. Those patients with tumor regression had significantly better progression free and overall survivals than did patients with no chemotherapy regressions (medians of 258 days vs. 136 days and 356 days vs. 150 days respectively). The original bleomycin dose had to be reduced by 50 {\%} primarily because of excessive radiation esophagitis that has not been reported with use of either the CAP regimen or bleomycin along in conjunction with thoracic irradiation. An initial chemotherapy regression seems to be a good prognosticator for progression-free and overall survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy.",
keywords = "Chemotherapy, Radiation therapy, Squamous cell lung cancer",
author = "Eagan, {Robert T.} and Fleming, {Thomas R.} and Lee, {Robert E.} and Ingle, {James N.} and Stephen Frytak and Creagan, {Edward T.}",
year = "1980",
doi = "10.1016/0360-3016(80)90328-4",
language = "English (US)",
volume = "6",
pages = "879--883",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy

AU - Eagan, Robert T.

AU - Fleming, Thomas R.

AU - Lee, Robert E.

AU - Ingle, James N.

AU - Frytak, Stephen

AU - Creagan, Edward T.

PY - 1980

Y1 - 1980

N2 - Twenty-two patients with limited unresectable squamous cell lung cancer were treated with 6 courses of combination chemotherapy consisting of cyclophosphamide, adriamycin, cisplatin, and bleomycin (CAP-Bleo) and short-course thoracic irradiation started after the first 4 weeks of chemotherapy. Of 20 patients with visible tumor who were treated with 4 weeks of chemotherapy alone, 10 (50 %) had a tumor regression in that 4 week period and 10 did not. Those patients with tumor regression had significantly better progression free and overall survivals than did patients with no chemotherapy regressions (medians of 258 days vs. 136 days and 356 days vs. 150 days respectively). The original bleomycin dose had to be reduced by 50 % primarily because of excessive radiation esophagitis that has not been reported with use of either the CAP regimen or bleomycin along in conjunction with thoracic irradiation. An initial chemotherapy regression seems to be a good prognosticator for progression-free and overall survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy.

AB - Twenty-two patients with limited unresectable squamous cell lung cancer were treated with 6 courses of combination chemotherapy consisting of cyclophosphamide, adriamycin, cisplatin, and bleomycin (CAP-Bleo) and short-course thoracic irradiation started after the first 4 weeks of chemotherapy. Of 20 patients with visible tumor who were treated with 4 weeks of chemotherapy alone, 10 (50 %) had a tumor regression in that 4 week period and 10 did not. Those patients with tumor regression had significantly better progression free and overall survivals than did patients with no chemotherapy regressions (medians of 258 days vs. 136 days and 356 days vs. 150 days respectively). The original bleomycin dose had to be reduced by 50 % primarily because of excessive radiation esophagitis that has not been reported with use of either the CAP regimen or bleomycin along in conjunction with thoracic irradiation. An initial chemotherapy regression seems to be a good prognosticator for progression-free and overall survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy.

KW - Chemotherapy

KW - Radiation therapy

KW - Squamous cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0018947929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018947929&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(80)90328-4

DO - 10.1016/0360-3016(80)90328-4

M3 - Article

VL - 6

SP - 879

EP - 883

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 7

ER -